Ocugen to Host Conference Call on Friday, May 7 at 8:30 a.m. ET to Discuss First Quarter 2021 Financial Results and Provide Business Update
Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical firm, announced it will host a conference call on May 7, 2021, at 8:30 a.m. ET to discuss first-quarter 2021 financial results and provide a business update. A pre-market earnings announcement will precede the call. The company focuses on gene therapies for blindness and co-developing Bharat Biotech's COVAXIN™ COVID-19 vaccine for the U.S. market. Investors can access the call via dial-in or webcast, which will be archived for 45 days.
- Focus on gene therapies for curing blindness, indicating potential for significant market growth.
- Co-development of COVAXIN™ vaccine shows commitment to addressing urgent health needs.
- None.
MALVERN, Pa., May 03, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a conference call to discuss its first quarter 2021 financial results and provide a business update at 8:30 a.m. ET on Friday, May 7, 2021.
Ocugen will issue a pre-market earnings announcement the same day. Investors are invited to participate on the call using the following details:
| Dial-In Number: | (844) 873-7330 (U.S.) or (602) 563-8473 (international) | |
| Conference ID: | 9757658 | |
| Webcast: | Available in the “Investors” section of the Ocugen website by clicking here and archived for approximately 45 days following the call | |
About Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many,” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. market. For more information, please visit www.ocugen.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. Such forward-looking statements within this press release include, without limitation, the intended use of net proceeds from the registered direct offering. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as market and other conditions. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.
Ocugen Contact:
Ocugen, Inc.
Sanjay Subramanian
CFO and Head of Corp. Dev.
IR@Ocugen.com
Media Contact:
LaVoieHealthScience
Lisa DeScenza
ldescenza@lavoiehealthscience.com
+1 978-395-5970
FAQ
What date is Ocugen's first quarter earnings call scheduled?
How can I access the earnings call for Ocugen?
What is Ocugen focused on developing?
What are the potential treatments being developed by Ocugen?
